• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

作者信息

Weinshenker B G, Rice G P, Noseworthy J H, Carriere W, Baskerville J, Ebers G C

机构信息

Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.

出版信息

Brain. 1991 Apr;114 ( Pt 2):1045-56. doi: 10.1093/brain/114.2.1045.

DOI:10.1093/brain/114.2.1045
PMID:2043940
Abstract

A multivariate hierarchical analysis was used to assess the significance of several demographic and clinical factors in multiple sclerosis patients. We used the time to reach level 6 on the disability status scale (DSS) of Kurtzke as endpoint. Several factors at presentation were significantly associated with an adverse outcome including older age at onset, male sex, cerebellar involvement or insidious onset of a motor deficit as first symptom. Factors ascertained later which were associated significantly with a worse outcome, even after controlling for those previously mentioned, included persisting deficits in brainstem, cerebellar or cerebral systems, a higher frequency of attacks in the first 2 yrs after onset of disease, a short first interattack interval and higher DSS at 2 yrs and 5 yrs from onset. An analysis similar to multiple regression was used to generate predictive models which permit the calculation of the median time to DSS 6 for patients with a given set of covariates. The goodness of fit of these models to the data and their predictive accuracy are discussed.

摘要

相似文献

1
The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.
Brain. 1991 Apr;114 ( Pt 2):1045-56. doi: 10.1093/brain/114.2.1045.
2
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.多发性硬化症的自然史:一项基于地域的研究。5. 原发性进行性多发性硬化症的临床特征及自然史。
Brain. 1999 Apr;122 ( Pt 4):625-39. doi: 10.1093/brain/122.4.625.
3
The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.
Brain. 1991 Apr;114 ( Pt 2):1057-67. doi: 10.1093/brain/114.2.1057.
4
Age at disability milestones in multiple sclerosis.多发性硬化症中达到残疾里程碑的年龄。
Brain. 2006 Mar;129(Pt 3):595-605. doi: 10.1093/brain/awh714. Epub 2006 Jan 16.
5
Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis.苏格兰东北部多发性硬化症的临床情况,特别涉及其病程和预后。
Brain. 1990 Dec;113 ( Pt 6):1597-628. doi: 10.1093/brain/113.6.1597.
6
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.
Brain. 1989 Dec;112 ( Pt 6):1419-28. doi: 10.1093/brain/112.6.1419.
7
Multiple sclerosis in Australia: prognostic factors.澳大利亚的多发性硬化症:预后因素。
J Clin Neurosci. 2000 Jan;7(1):16-9. doi: 10.1054/jocn.1998.0107.
8
Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.采用一种经过验证的评估临床事件的方法对多发性硬化病程的预测因素进行多变量分析。
J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):300-6. doi: 10.1136/jnnp.58.3.300.
9
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.多发性硬化症的自然史:一项基于地域的研究。I. 临床病程与残疾情况
Brain. 1989 Feb;112 ( Pt 1):133-46. doi: 10.1093/brain/112.1.133.
10
Prediction of outcome in multiple sclerosis based on multivariate models.基于多变量模型的多发性硬化症预后预测
J Neurol. 1994 Oct;241(10):597-604. doi: 10.1007/BF00920623.

引用本文的文献

1
Neuroimaging phenotype characterization of early aggressive and late severe multiple sclerosis: a case-control study.早期侵袭性和晚期重症多发性硬化的神经影像学表型特征:一项病例对照研究。
Brain Commun. 2025 Jun 24;7(4):fcaf254. doi: 10.1093/braincomms/fcaf254. eCollection 2025.
2
Choosing initial MS therapy; personal, disease, and medication factors.选择初始多发性硬化症治疗方法;个人、疾病及药物因素
Neurotherapeutics. 2025 Jul;22(4):e00582. doi: 10.1016/j.neurot.2025.e00582. Epub 2025 Apr 10.
3
Predictors of early disability accumulation in newly diagnosed multiple sclerosis: clinical, imaging and cerebrospinal fluid measures.
新诊断多发性硬化症早期残疾累积的预测因素:临床、影像学和脑脊液指标
J Neurol Neurosurg Psychiatry. 2025 Feb 17. doi: 10.1136/jnnp-2024-335037.
4
Exploring the role of sex hormones and gender diversity in multiple sclerosis.探索性激素和性别多样性在多发性硬化症中的作用。
Nat Rev Neurol. 2025 Jan;21(1):48-62. doi: 10.1038/s41582-024-01042-x. Epub 2024 Dec 11.
5
Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.将侵袭性多发性硬化的临床和 MRI 拟议标准与神经轴突和神经胶质损伤的血清和脑脊液标志物相匹配。
J Neurol. 2024 Jun;271(6):3512-3526. doi: 10.1007/s00415-024-12299-z. Epub 2024 Mar 27.
6
Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.迟发性多发性硬化的临床特征和长期预后:一项瑞典全国性研究。
Neurology. 2024 Mar 26;102(6):e208051. doi: 10.1212/WNL.0000000000208051. Epub 2024 Feb 23.
7
Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients.通过总自由基捕获抗氧化参数测定的多发性硬化症患者队列中的血浆抗氧化潜力。
Brain Behav. 2024 Jan;14(1):e3377. doi: 10.1002/brb3.3377.
8
Prodromal multiple sclerosis: considerations and future utility.前驱期多发性硬化症:考虑因素和未来应用。
J Neurol. 2024 Apr;271(4):2129-2140. doi: 10.1007/s00415-023-12173-4. Epub 2024 Feb 11.
9
Development of a predictive model for predicting disability after optic neuritis: a secondary analysis of the Optic Neuritis Treatment Trial.视神经炎后残疾预测模型的开发:视神经炎治疗试验的二次分析
Front Neurol. 2024 Jan 8;14:1326261. doi: 10.3389/fneur.2023.1326261. eCollection 2023.
10
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.一项关于阿仑单抗在真实世界多发性硬化症患者队列中疗效的为期五年的前瞻性单中心观察性研究。
Front Neurol. 2023 Sep 21;14:1265354. doi: 10.3389/fneur.2023.1265354. eCollection 2023.